Keyphrases
Pancreatic Ductal Adenocarcinoma
75%
Neoadjuvant
74%
Overall Survival
65%
Metastatic Pancreatic Ductal Adenocarcinoma
62%
Tumor Microenvironment
61%
Allogeneic
57%
Irinotecan
54%
Therapeutic Vaccine
53%
Phase II Study
45%
Metastatic Colorectal Cancer (mCRC)
45%
Guadecitabine
45%
Phase I Trial
45%
Nivolumab
45%
Low-dose Cyclophosphamide
38%
Neoadjuvant Therapy
36%
Cellular Immune Response
35%
T Cells
34%
CD137
34%
Effector T Cells
34%
Vaccine Response
33%
Lymphoid Aggregates
32%
DNA Vaccine
32%
Dose Level
30%
Viral Replication
27%
Pancreatic Tumor Cells
27%
Programmed Death-ligand 1 (PD-L1)
26%
Pancreatic Cancer
26%
Plasmid
26%
Macaque
26%
Disease-free Survival
26%
Pancreatic Tumor
22%
Change Analysis
22%
Anti-PD-1 Therapy
22%
TAS-102
22%
Clinical Trials
22%
Memory Subsets
22%
Epigenetic Modulators
22%
Advanced Colorectal Cancer
22%
Immune Response
22%
Pancreatic Adenocarcinoma
22%
Multi-omics Analysis
22%
Interleukin-15 (IL-15)
22%
Setpoint Following
22%
Viral Load
22%
Microsatellite Stable
22%
Ipilimumab
22%
Trametinib
22%
Pembrolizumab
22%
Intravenous Ascorbate
22%
CCL27
22%
Immunology and Microbiology
Vaccine Efficacy
100%
Plasmid
68%
Simian Immunodeficiency Virus
59%
Immune Response
54%
Overall Survival
50%
T Cell
49%
DNA Vaccine
48%
Rhesus Monkey
45%
Interleukin 15
45%
Nivolumab
42%
Adoptive Immunity
41%
CD8
40%
Cyclophosphamide
39%
Low Drug Dose
39%
Arm
36%
Viral Load
36%
Immunotherapy
36%
T-Helper Cell
33%
Cytotoxic T-Cell
33%
Viral Replication
32%
Human Immunodeficiency Virus
29%
Vaccination Policy
27%
Macaca
26%
Vaccine Adjuvant
25%
Monospecific Antibody
22%
Multi-Omics
22%
Interleukin 12
22%
CCL28
22%
Cutaneous T Cell Attracting Chemokine
22%
Macaca fascicularis
22%
Human Immunodeficiency Virus Antigen
22%
Agonist
22%
Tumor Cell Vaccine
22%
Macrophage
22%
Granulocyte
22%
Disease Free Survival
22%
Human Immunodeficiency Virus 1
21%
Allele
18%
Antigen Specificity
16%
CCL27
15%
Lymphocyte
13%
Major Histocompatibility Complex
13%
CD40 Ligand
13%
Neutrophil Granulocyte
11%
Granulocyte Macrophage Colony-Stimulating Factor
10%
Urelumab
9%
Mouse
8%
Effector Cell
7%
CD4
7%
Adjuvant
6%
Medicine and Dentistry
Pancreas Adenocarcinoma
61%
Arm
48%
Pancreas Cancer
45%
Pancreas Tumor
45%
Overall Survival
42%
Macrophage
36%
Cyclophosphamide
36%
Low Drug Dose
36%
Tumor Microenvironment
28%
Neoplasm
27%
Pancreatic Ductal Adenocarcinoma
27%
Tumor Cell
25%
Ipilimumab
22%
Tumor Cell Vaccine
22%
Tumor Vaccine
22%
Pembrolizumab
22%
Radioimmunotherapy
22%
Maintenance Therapy
22%
Colorectal Cancer
22%
Stereotactic Body Radiation Therapy
22%
Cellular Infiltration
22%
T Cell
22%
Granulocyte
22%
Vaccine Adjuvant
22%
Immunotherapy
18%
Whole Body Radiation
17%
Disease Free Survival
12%
DNA Methyltransferase
11%
Histone Deacetylase
11%
Cytotoxic T-Cell
11%
Clinical Trial
10%
Effector Cell
10%
Neoadjuvant Therapy
10%
Thrombocytopenia
8%
Granulocyte Macrophage Colony Stimulating Factor
7%
Surgery
6%
Azacitidine
5%
Nausea
5%
Immune Checkpoint Inhibitor
5%
Adverse Event
5%
Drive
5%
Anorexia
5%
Anemia
5%
Lymphocytopenia
5%
Immune Cell Infiltration
5%
Programmed Death-Ligand 1
5%
Progression Free Survival
5%
DNA Mismatch Repair
5%
Immunosuppressive Drug
5%
Radiation Therapy
5%
